Epileptic Seizures Treatment Market Report 2026

The epileptic seizures treatment market size has grown strongly in recent years. It will grow from $3.62 billion in 2025 to $3.86 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to antiepileptic drug availability, seizure disorder prevalence, neurologist specialization growth, hospital neurology services, treatment guideline evolution.

The epileptic seizures treatment market size is expected to see strong growth in the next few years. It will grow to $4.83 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to gene-based therapies, neuromodulation innovation, precision neurology adoption, wearable seizure monitoring, early diagnosis rates. Major trends in the forecast period include growing adoption of combination drug therapy, increased use of neuromodulation techniques, expansion of cannabidiol-based treatments, rising focus on personalized seizure management, emphasis on reducing drug resistance.

The rising prevalence of epilepsy is expected to drive the growth of the epileptic seizures treatment market in the coming years. Epilepsy is a neurological disorder marked by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain, leading to symptoms such as convulsions, loss of consciousness, and sensory or behavioral disturbances. The increasing prevalence of epilepsy can be attributed to factors such as higher survival rates among individuals with brain injuries or strokes and the growth of the aging population. Effective treatments for epileptic seizures, mainly through antiepileptic drugs (AEDs), can significantly reduce the frequency and severity of seizures. These medications help stabilize neuronal activity in the brain, maintaining seizure-free periods and supporting patients’ daily functioning and overall quality of life. For instance, in February 2024, the World Health Organization, a Switzerland-based United Nations public health agency, reported that approximately 50 million people globally were living with epilepsy, making it one of the most common neurological disorders worldwide. Each year, about 5 million new cases are diagnosed. Therefore, the rising prevalence of epilepsy is driving the growth of the epileptic seizures treatment market.

Major companies in the epileptic seizures treatment market are focusing on developing innovative solutions, such as cannabis-based drugs, to provide effective alternatives for patients who do not respond to conventional antiseizure medications. Cannabis-based drugs are pharmaceutical products derived from the cannabis plant, formulated to leverage the therapeutic properties of cannabinoids. These drugs are primarily used for their anticonvulsant effects, helping to reduce the frequency and severity of seizures in patients with epilepsy. For instance, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a Drug Controller General of India (DCGI)-approved prescription cannabis-based medicine to treat seizures in children, particularly those with Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex. This cannabidiol (CBD) oral solution contains less than 0.1% tetrahydrocannabinol (THC) and has demonstrated efficacy in reducing seizures, particularly in cases where conventional antiseizure medications have failed. Clasepi is designed for severe epilepsy cases but is not recommended for individuals with allergies to cannabidiol or its ingredients.

In October 2024, H. Lundbeck A/S, a Denmark-based biopharmaceutical company, acquired Longboard Pharmaceuticals, Inc. for US$ 2.6 billion. Through this acquisition, Lundbeck aims to strengthen its epileptic seizure treatment portfolio by integrating Longboard’s investigational therapy, bexicaserin, which is being developed for seizures associated with developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome. Longboard Pharmaceuticals, Inc. is a US-based company dedicated to developing novel therapies for neurological disorders.

Major companies operating in the epileptic seizures treatment market are Pfizer Inc., Johnson & Johnson Service Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Co. Ltd., Medtronic plc, GE HealthCare Technologies Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Dragerwerk AG & Co.KGaA, H. Lundbeck A/S, Apotex Inc., Masimo Corporation, Fisher & Paykel Healthcare Limited, Inspiration Healthcare Group Plc., Phoenix Medical Systems (P) Ltd., Marinus Pharmaceuticals Inc., Alexza Pharmaceuticals Inc., Neurelis Inc., Veriton Pharma.

North America was the largest region in the epileptic seizures treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epileptic seizures treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epileptic seizures treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the epileptic seizures treatment market by increasing costs of imported antiepileptic drugs, neuromodulation devices, and diagnostic tools. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported therapies. These tariffs increase treatment costs by raising medication prices and device-related expenses for long-term seizure management, potentially affecting patient adherence. However, they support local pharmaceutical manufacturing, encouraging domestic production of antiepileptic drugs and regional development of seizure management solutions.

The epileptic seizures treatment market research report is one of a series of new reports that provides epileptic seizures treatment market statistics, including epileptic seizures treatment industry global market size, regional shares, competitors with a epileptic seizures treatment market share, detailed epileptic seizures treatment market segments, market trends and opportunities, and any further data you may need to thrive in the epileptic seizures treatment industry. This epileptic seizures treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epileptic seizure treatment refers to medical interventions and therapies designed to manage and control seizures in individuals with epilepsy, a neurological disorder marked by recurrent and unpredictable seizures. Treatment options may include medications, lifestyle changes, dietary therapies, and other interventions tailored to each patient’s needs, aiming to reduce seizure frequency and severity while improving overall quality of life.

The main types of epileptic seizure treatment include established treatment practices, emerging drugs, and individual therapies. Treatment practices encompass the recognized and evolving methods used by healthcare professionals to manage and alleviate symptoms of various medical conditions, including pharmacological treatments, surgical procedures, and non-pharmacological therapies. These treatments are applied to different seizure types, such as partial seizures, generalized seizures, and unclassified seizures, using multiple administration routes, including oral or buccal, nasal, rectal, and parenteral. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The epileptic seizures treatment market consists of revenues earned by entities by providing services, such as medication management, rehabilitation services, diagnostic services, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The epileptic seizures treatment market also includes sales of anti-epileptic drugs, surgical implants, ketogenic diet products, seizure alarms, and vagus nerve stimulators which are used in providing the services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.